PMVP
PMV Pharmaceuticals, Inc. NASDAQ Listed Sep 25, 2020$1.15
After hrs
$1.15
+0.00%
Mkt Cap $61.3M
52w Low $0.96
20.3% of range
52w High $1.88
50d MA $1.28
200d MA $1.30
P/E (TTM)
—
EV/EBITDA
—
P/B
0.6x
Debt/Equity
0.0x
ROE
-74.2%
P/FCF
-0.8x
RSI (14)
52.20
ATR (14)
$0.07
Beta
1.40
50d MA
$1.28
200d MA
$1.30
Avg Volume
376.8K
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.
8 Clarke Drive · Princeton, NJ 08512 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 6, 2026 | AMC | -0.40 | -0.34 | +15.0% | 1.64 | +0.6% | -0.6% | -0.6% | -1.2% | -1.2% | -1.3% | — |
| Nov 12, 2025 | AMC | -0.40 | -0.40 | +0.0% | 1.42 | +1.4% | -4.2% | +1.5% | +2.9% | -1.4% | -2.9% | — |
| Aug 7, 2025 | AMC | -0.39 | -0.41 | -5.1% | 1.45 | +1.4% | +2.1% | -5.4% | +1.4% | +7.0% | +2.0% | — |
| May 9, 2025 | AMC | -0.37 | -0.34 | +8.1% | 0.88 | +1.1% | -2.1% | -1.4% | -0.8% | -0.9% | +3.3% | — |
| Mar 3, 2025 | AMC | -0.38 | -0.45 | -18.4% | 1.32 | +0.0% | -2.3% | +6.2% | -10.2% | +0.0% | -0.8% | — |
| Nov 7, 2024 | AMC | -0.35 | -0.37 | -5.7% | 1.78 | +2.2% | -2.2% | +0.6% | -4.6% | -1.2% | -3.0% | — |
| Aug 8, 2024 | AMC | -0.34 | -0.02 | +94.1% | 1.46 | +0.7% | -1.4% | +3.5% | -0.7% | -2.0% | +6.2% | — |
| May 9, 2024 | AMC | -0.35 | -0.30 | +14.3% | 2.10 | +0.5% | -2.9% | +4.4% | +0.5% | +0.9% | -0.5% | — |
| Feb 29, 2024 | AMC | -0.39 | -0.31 | +20.5% | 1.85 | -2.7% | +1.6% | -0.5% | +0.5% | +2.7% | -3.6% | — |
| Nov 9, 2023 | AMC | -0.45 | -0.34 | +24.4% | 1.90 | +0.0% | +5.3% | +1.5% | +9.9% | +8.1% | -4.6% | — |
| Aug 9, 2023 | AMC | -0.47 | -0.38 | +19.1% | 8.67 | +1.4% | +1.4% | +1.6% | -8.7% | -4.5% | -6.4% | — |
| May 10, 2023 | AMC | -0.48 | -0.42 | +12.5% | 5.46 | +0.9% | +3.3% | +1.1% | +1.4% | -2.8% | +0.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.28 | $1.26 | -1.6% | -1.6% | +0.8% | -2.4% | -2.4% | -4.1% |
| Aug 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.55 | $1.58 | +1.9% | +3.9% | -1.2% | -3.8% | +1.3% | +3.2% |
| May 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.80 | $1.83 | +1.7% | -0.6% | +1.7% | -4.9% | -1.2% | +1.2% |
| May 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.13 | $2.14 | +0.5% | +0.5% | +0.9% | -0.5% | -2.3% | +5.2% |
| Mar 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.93 | $1.95 | +1.0% | -3.6% | -8.6% | -4.1% | +1.2% | -3.0% |
| Oct 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.00 | $2.06 | +3.0% | -11.0% | +10.4% | +7.6% | -16.8% | -15.3% |
| Aug 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.79 | $8.78 | -0.1% | +1.6% | -8.7% | -4.5% | -6.4% | -1.4% |
| May 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.62 | $5.72 | +1.8% | +0.5% | +0.2% | -0.2% | +1.4% | -1.0% |
| May 11 | Oppenheimer | Maintains | Outperform → Outperform | — | $5.46 | $5.51 | +0.9% | +3.3% | +1.1% | +1.4% | -2.8% | +0.5% |
| Mar 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.45 | $5.51 | +1.1% | +0.7% | -1.3% | -8.7% | +2.2% | -0.6% |
| Mar 2 | Oppenheimer | Maintains | Outperform → Outperform | — | $6.19 | $6.14 | -0.8% | -4.6% | -0.1% | -1.7% | +3.6% | -2.5% |
| Nov 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.29 | $10.41 | +1.2% | -2.1% | -2.8% | -0.3% | +5.0% | -1.8% |
| Jun 9 | Oppenheimer | Maintains | Outperform → Outperform | — | $10.24 | $10.27 | +0.3% | +1.2% | -6.9% | -4.3% | +2.3% | +4.4% |
| May 24 | Goldman Sachs | Maintains | Buy → Buy | — | $15.00 | $14.67 | -2.2% | -6.1% | -7.1% | +0.9% | +16.0% | -23.3% |
| Mar 2 | Oppenheimer | Upgrade | Perform → Outperform | — | $16.65 | $17.81 | +7.0% | +4.9% | -6.2% | -2.1% | +5.9% | +2.8% |
| Sep 22 | Goldman Sachs | Upgrade | Neutral → Buy | — | $27.44 | $30.00 | +9.3% | +3.5% | +4.3% | -1.2% | +0.8% | +0.9% |
| Aug 19 | Oppenheimer | Maintains | Perform → Perform | — | $32.45 | $31.11 | -4.1% | -12.1% | -0.2% | +8.1% | +2.1% | -2.0% |
| Aug 2 | Guggenheim | Maintains | Buy → Buy | — | $34.01 | $34.69 | +2.0% | +1.1% | -0.8% | +6.8% | +0.1% | +0.4% |
| Jul 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $35.66 | $36.03 | +1.0% | -2.3% | -2.4% | +1.1% | -0.8% | +6.8% |
No insider trades available.
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Bml Capital Management, Llc | 5,320,000 | $7M | Added | Mar 2026 |
| 2 | Tang Capital Management Llc | 4,940,000 | $6M | Added | Dec 2025 |
| 3 | Acadian Asset Management Llc | 2,215,894 | $3M | Added | Mar 2026 |
| 4 | Vanguard Capital Management Llc | 1,974,906 | $2M | New | Mar 2026 |
| 5 | Two Sigma Investments, Lp | 1,884,530 | $2M | Added | Mar 2026 |
| 6 | Stonepine Capital Management, Llc | 708,102 | $878K | Reduced | Mar 2026 |
| 7 | Walleye Capital Llc | 671,388 | $833K | — | Mar 2026 |
| 8 | Longaeva Partners L.p. | 552,027 | $685K | New | Mar 2026 |
| 9 | Jane Street Group, Llc | 498,641 | $623K | Added | Dec 2025 |
| 10 | Marshall Wace, Llp | 434,093 | $538K | Reduced | Mar 2026 |
| 11 | Assenagon Asset Management S.a. | 360,786 | $447K | Added | Mar 2026 |
| 12 | Rbf Capital, Llc | 324,400 | $402K | — | Mar 2026 |
| 13 | Bank Of America Corp /de/ | 240,531 | $298K | Added | Mar 2026 |
| 14 | Adar1 Capital Management, Llc | 231,008 | $286K | New | Mar 2026 |
| 15 | Morgan Stanley | 197,750 | $247K | Added | Dec 2025 |
| 16 | Verdad Advisers, Lp | 180,161 | $223K | New | Mar 2026 |
| 17 | Bit Capital Gmbh | 123,555 | $153K | New | Mar 2026 |
| 18 | Northern Trust Corp | 115,422 | $143K | Reduced | Mar 2026 |
| 19 | Velan Capital Investment Management Lp | 73,000 | $91K | Added | Mar 2026 |
| 20 | Pnc Financial Services Group, Inc. | 68,292 | $85K | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 17
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Meridian Small Cap Growth Fund | 1,078,920 | $1M | Mar 2026 |
| 2 | Ultra-Small Company Fund | 331,453 | $411K | Mar 2026 |
| 3 | Fidelity Extended Market Index Fund | 221,754 | $377K | Feb 2026 |
| 4 | iShares Micro-Cap ETF | 114,304 | $142K | Mar 2026 |
| 5 | Fidelity Total Market Index Fund | 71,190 | $121K | Feb 2026 |
| 6 | Fidelity Series Total Market Index Fund | 59,924 | $102K | Feb 2026 |
| 7 | Ultra-Small Company Market Fund | 76,900 | $95K | Mar 2026 |
| 8 | NVIT Small Cap Value Fund | 45,804 | $57K | Mar 2026 |
| 9 | SMALL CAP EQUITY FUND | 36,833 | $46K | Mar 2026 |
| 10 | NVIT Multi-Manager Small Company Fund | 24,191 | $30K | Mar 2026 |
| 11 | Multi-Manager Small Cap Equity Strategies Fund | 13,237 | $23K | Feb 2026 |
| 12 | Fidelity Nasdaq Composite Index Fund | 12,039 | $20K | Feb 2026 |
| 13 | Small Cap Core Fund | 6,605 | $8K | Mar 2026 |
| 14 | Avantis Total Equity Markets ETF | 4,716 | $8K | Feb 2026 |
| 15 | LVIP Dimensional U.S. Core Equity 1 Fund | 356 | $441 | Mar 2026 |
| 16 | Knights of Columbus U.S. ALL CAP INDEX FUND | 257 | $278 | Jan 2026 |
| 17 | Guggenheim Active Allocation Fund | 156 | $265 | Feb 2026 |
Valuation
Market Cap
$61.3M
Enterprise Value
-$50.5M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
-0.03x
P/B
0.58x
P/S
—
P/FCF
-0.84x
EV/EBITDA
—
Shares Out
52.5M
Financials (TTM)
Revenue
$0
Net Income
-$78.3M
EBITDA
-$78.2M
Free Cash Flow
-$73.6M
Op Cash Flow
-$73.6M
EPS Basic
$-1.48
EPS Diluted
$-1.49
EPS Forward
$-1.57
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$116.6M
Total Liab.
$11.8M
Total Equity
$104.7M
Cash
$112.9M
LT Debt
$435K
Book Value/Sh
$1.99
Debt/Equity
0.01x
Current Ratio
10.09
Quick Ratio
10.09
Returns & Growth
ROE
-74.2%
ROA
-66.7%
ROIC
-79.5%
Rev Growth YoY
+0.0%
EPS Growth YoY
-30.0%
Price Returns
2W
-9.8%
1M
-13.7%
3M
-29.4%
6M
-9.1%
12M
+36.6%
Technicals
52W High
$1.88
52W Low
$0.96
50d MA
$1.28
200d MA
$1.30
RSI (14)
52.20
ATR (14)
$0.07
Beta
1.40
Avg Volume
377K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$18.00
High
$36.00
Low
$5.00
Median
$15.50
Data updated apr 26, 2026 8:12pm
· Source: financialmodelingprep.com